News

07.28.22

Press Release

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

SEATTLE, Wash and VANCOUVER, British Columbia, July 28, 2022 —  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program…

/Read More

07.01.22

Press Release

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE, Wash. and VANCOUVER, British Columbia, July 1, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees. Achieve’s Board of Directors…

/Read More

06.29.22

Press Release

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation

SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the…

/Read More

06.21.22

Press Release

Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference

SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the H.C. Wainwright 1st Annual Mental Health Conference. The Conference is…

/Read More

06.01.22

Press Release

Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users

Company awarded $2.5 million to enable initiation of the Phase 2 ORCA-V1 clinical trial SEATTLE and VANCOUVER, British Columbia, June 1, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it…

/Read More